Biogen PT receives Investment Bank Analyst Rating Update
By Sam Boughedda A Jefferies equity analyst told investors in a note on Monday that they believe Biogen (NASDAQ:BIIB) could become a strategic asset. In a note focused on the Phase...
(Reuters) -Biogen Inc's treatment for a rare type of amyotrophic lateral sclerosis (ALS) was accepted for review by the U.S. health regulator, weeks after follow-up analyses of...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Wednesday, the Russell 2000 (IWM) made a divergence in price and our momentum indicator Real Motion (RM). In the chart below we can see that while the price has broken underneath...
Key Takeaways: Q4 earnings reports turned a corner last week with impressive results from Big Tech names EPS growth normalizes on a QoQ basis, the number of companies showing...
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
|Average||239.69 (+21.19% Upside)|
|No. of Analysts||26|